MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.52
+0.74
+5.01%
Opening 14:11 11/19 EST
OPEN
14.85
PREV CLOSE
14.78
HIGH
15.73
LOW
14.70
VOLUME
129.68K
TURNOVER
--
52 WEEK HIGH
20.79
52 WEEK LOW
10.75
MARKET CAP
781.84M
P/E (TTM)
-8.3983
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RCKT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RCKT News

  • Rocket Pharmaceuticals EPS beats by $0.13
  • seekingalpha.11/07 17:40
  • Rocket Pharmaceuticals Q3 EPS $(0.38) Up From $(0.40) YoY
  • Benzinga.11/07 13:18
  • Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
  • Business Wire.11/07 12:00
  • Benzinga's Top Upgrades, Downgrades For November 6, 2019
  • Benzinga.11/06 14:56

More

Industry

Biotechnology & Medical Research
+2.04%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.
More

Webull offers Rocket Pharmaceuticals Inc (RCKT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.